Synairgen makes progress in H1 as it moves towards phase II trial of lead asset

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Marsden provided updates on Synairgen's antiviral treatment, SNG001, and plans for a trial in mechanically ventilated patients suffering from severe viral lung infections. Marsden also touched on recent changes in Synairgen's leadership, including the appointment of Mark Parry-Billings as the new chairman. Parry-Billings, who brings extensive experience in inhaled anti-infective treatments, is set to take on his role in October, a move Marsden sees as a significant step forward for the company. Looking ahead, Marsden mentioned that more details on the phase II trial of its lead asset and its funding would be released soon. As Synairgen progresses, the company remains focused on improving outcomes for patients with severe viral infections. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications to stay updated with Synairgen’s latest developments. #Synairgen #SNG001 #ClinicalTrials #VentilatorCare #AntiviralTreatment #BiotechInnovation #PharmaceuticalUpdates #RichardMarsden #ProactiveInvestors #HealthcareInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnewsSynairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden takes Proactive's Stephen Gunnion through the progress made in the six months to June 30 and upcoming milestones. Marsden provided updates on Synairgen's antiviral treatment, SNG001, and plans for a trial in mechanically ventilated patients suffering from severe viral lung infections. Marsden also touched on recent changes in Synairgen's leadership, including the appointment of Mark Parry-Billings as the new chairman. Parry-Billings, who brings extensive experience in inhaled anti-infective treatments, is set to take on his role in October, a move Marsden sees as a significant step forward for the company. Looking ahead, Marsden mentioned that more details on the phase II trial of its lead asset and its funding would be released soon. As Synairgen progresses, the company remains focused on improving outcomes for patients with severe viral infections. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications to stay updated with Synairgen’s latest developments. #Synairgen #SNG001 #ClinicalTrials #VentilatorCare #AntiviralTreatment #BiotechInnovation #PharmaceuticalUpdates #RichardMarsden #ProactiveInvestors #HealthcareInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews